Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
The latest announcement is out from Vor Biopharma ( (VOR) ).
On May 19, 2024, Vor Biopharma Inc. appointed Robert Ang, the company’s President and CEO, as its principal financial officer and principal accounting officer. This appointment does not involve any new arrangements, family relationships, or material interests in related party transactions, indicating a seamless transition in leadership roles without impacting existing contracts or plans.
The most recent analyst rating on (VOR) stock is a Hold with a $0.40 price target. To see the full list of analyst forecasts on Vor Biopharma stock, see the VOR Stock Forecast page.
Spark’s Take on VOR Stock
According to Spark, TipRanks’ AI Analyst, VOR is a Underperform.
Vor Biopharma faces significant financial challenges, with no revenue and ongoing losses. Technical indicators suggest weak market sentiment, and the lack of positive valuation metrics further underscores the risk. Investors should be cautious due to the high financial risk and uncertainty.
To see Spark’s full report on VOR stock, click here.
More about Vor Biopharma
Average Trading Volume: 1,761,559
Technical Sentiment Signal: Sell
Current Market Cap: $21.93M
See more data about VOR stock on TipRanks’ Stock Analysis page.